GlassScriptPhysician profile
Marc I Lavin
NPI 1326048638
$4,171.11
in general payments reported to CMS, 2019-2025
32 companies · $632 in 2025
The $632 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,192 · 2020: $530 · 2021: $273 · 2022: $376 · 2023: $526 · 2024: $642 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,800.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $755.83 | 2019-2025 | Repatha, Otezla, Prolia |
| Abbvie INC. | $474.06 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $419.84 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $341.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $320.16 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $232.88 | 2019 | |
| Pfizer INC. | $207.58 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $190.00 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $133.06 | 2022-2023 | Freestyle Libre 2 |
| Medtronic Vascular, INC. | $131.48 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $116.46 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Novo Nordisk INC | $108.10 | 2019-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.75 | 2023-2025 | Jardiance, Tradjenta |
| Idorsia Pharmaceuticals US INC | $64.26 | 2023-2025 | Quviviq, Quviviq |
| Amarin Pharma, INC. | $60.75 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $58.30 | 2019-2020 | |
| Almatica Pharma LLC | $55.56 | 2024-2025 | Loreev Xr |
| Astellas Pharma US INC | $54.47 | 2020-2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $48.57 | 2025 | |
| Radius Health, INC. | $45.84 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $43.30 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $28.55 | 2022 | |
| Horizon Therapeutics Plc | $28.31 | 2019 | |
| Shield Therapeutics INC | $26.60 | 2023 | Accrufer |
| Seqirus USA INC | $24.40 | 2025 | Fluad, Flucelvax |
| Sanofi-Aventis U.S. LLC | $22.16 | 2025 | |
| Alk-Abello, INC | $21.94 | 2024 | Odactra, Ragwitek, Grastek |
| Takeda Pharmaceuticals U.S.A., INC. | $20.91 | 2023 | Trintellix |
| Tolmar, INC. | $18.60 | 2025 | Jatenzo |
| Glaxosmithkline, LLC. | $18.48 | 2023 | Shingrix, Arexvy |
| Exact Sciences Corporation | $15.78 | 2023 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $12.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Lavin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.